


Global use of GPHF-Minilabs for the detection of falsified and substandard medicines



1
2-3
4-9
10-19
≥ 20

Africa	
Benin	1
Cape Verde	1
Central African Republic	1
Chad	1
Djibouti	1
Niger	1
Swaziland	1
Botswana	2
Congo PR	2
Gambia	2
Guinea-Equatorial	2
Ivory Coast	2
Lesotho	2
Mauritania	2
Namibia	2
Burkina Faso	3
Gabon	3
Guinea-Bissau	3
Sudan	3
Togo	3
Eritrea	4
Zimbabwe	4
South Sudan	5
Guinea-Conakry	6
Somalia	6

Asia

Malawi	7
Liberia	8
Burundi	9
Sierra Leone	10
Rwanda	12
Uganda	12
Mali	13
Senegal	13
Zambia	13
Cameroon	19
Mozambique	19
Kenya	20
Angola	22
Madagascar	24
Ethiopia	25
Ghana	31
Congo DR	32
Tanzania	55
Nigeria	59
466	229

America

Georgia	1
Maldives	1
Sri Lanka	1
Tadzhikistan	1
Uzbekistan	1
West Bank & Gaza	1
Bhutan	2
Kyrgyztan	3
Nepal	3
Kazakhstan	5
Bangladesh	7
India	16
Thailand	16
Afghanistan	17
Pakistan	18
Cambodia	19
Myanmar	26
Laos	29
Vietnam	62
Colombia	11
62	62

Pacific

Belize	1
Grenada	1
Guatemala	1
St. Lucia	1
Virgin Islands (brit.)	1
Brazil	2
Nicaragua	2
Surinam	2
Venezuela	3
Ecuador	4
Bolivia	5
Peru	6
Guyana	6
Haiti	7
USA*	9
Colombia	11
54	54

Europe

Fiji Islands	1
Samoa	1
Timor Leste	1
Australia*	2
Taiwan*	3
China*	4
Papua New Guinea	9
Philippines	14
Indonesia	19
Belgium*	1
Italy*	1
Netherlands*	1
Norway*	1
Spain*	1
Great Britain*	2
Switzerland*	2
Germany*	7
Russia*	9
25	25

Global
836

The GPHF-Minilab™

A mini-laboratory developed by the Global Pharma Health Fund (GPHF) to boost the medicines testing capacity at healthcare providers in developing countries. Focus on priority essential medicines, for example anti-infectives. Non-sophisticated, affordable and fit for use in the field. Supplied more than 800 times to 97 countries already. Minilabs save lives. For more, go to www.gphf.org.



A charitable organisation maintained exclusively by Merck

* For training and demonstration purposes only | Latest update December 2017